诚达药业：2026年第一次临时股东会决议公告

Group 1 - The core point of the article is that Chengda Pharmaceutical announced the approval of a proposal to use part of the raised funds to permanently supplement its working capital during the first extraordinary general meeting of shareholders in 2026 [2] Group 2 - The announcement was made on January 6, indicating the company's proactive approach to managing its financial resources [2]